Awardee OrganizationSCRIPPS RESEARCH INSTITUTE, THE
Description
Abstract Text
The goal of an initial SAR analysis is to understand the influence of structural changes in a way that allows a
reasonable prediction of which modification(s) may lead to improved properties. This analysis is therefore
tightly coupled with the chemists developing a working hypothesis and strategy for structure optimization. Each
class of hits will be profiled based on potency (biochemical/cellular), selectivity, solubility, bioavailability,
toxicity, and ease of synthesis. Issues will be identified for each class. Lead compounds are chosen from the
hit classes with the most desired profiles and sensible SAR for further improvement. If these experimental
data are not available, computational descriptors and models can be used to assess whether one structural
class is more amenable to optimization than another. We will also consider binding efficiency index (BEI) and
surface binding efficiency index (SEI). [65] For the production phase we plan to implement a number of
additional computational tools for such multidimensional SAR and SPR analyses using a variety of filters,
models, and visualization techniques to quickly and reproducibly rank chemical series or individual compounds
in the context of the probe development project.
As the probe optimization proceeds through iterative cycles, analyses performed for S1P receptors incjuded
QSAR, pharmacophore model development, and docking studies. Receptor structure-based design will be
applied if the target structure is known or a reasonable homology model of the target receptor can be built.
Industry standard pharmacophore- and shape-based modeling and visualization tools are available, and are
described in the informatics and resources section. In this case, each class of hits will be docked to the
receptor structure to find possible mode of action (binding mode). The favored mode of action should be
consistent with the initial SAR. The initial SAR, receptor structural information (if available), and experience in
medicinal chemistry will be combined in the design of second-generation molecules to overcome at least some
of the issues of lead classes. The compounds will be screened and profiled. The data will be utilized to refine
the SAR which in turn is applied in the design of next generation libraries until optimized compounds/probes
are obtained. The optimized lead should be improved over the initial hit as defined in Table 7. All probes and
their associated data will be made available to all researchers in accordance with the published RFA guidance.
No Sub Projects information available for 5U54MH084512-03 0007
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54MH084512-03 0007
Patents
No Patents information available for 5U54MH084512-03 0007
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54MH084512-03 0007
Clinical Studies
No Clinical Studies information available for 5U54MH084512-03 0007
News and More
Related News Releases
No news release information available for 5U54MH084512-03 0007
History
No Historical information available for 5U54MH084512-03 0007
Similar Projects
No Similar Projects information available for 5U54MH084512-03 0007